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To the Editor:
We read the article by Drs. Chudnoff, Nichols, and Levie with great interest and 
applaud their publication of Phase III data on 5 year follow-up after hysteroscopic 
sterilization [1]. However, we are concerned about their focus on perfect use, 
rather than real world use. Specifically, their evaluation of effectiveness was 
based on “women with successful bilateral placement of Essure inserts,” rather 
than women who attempted Essure. For example, the study excluded 4 women 
who became pregnant before undergoing a hysterosalpingogram (HSG), 15 
women who underwent hysterectomy, 1 woman who missed her 6 month follow-
up HSG, 1 woman who was incarcerated, 1 woman who had unsatisfactory device
placement, and 1 woman with leukemia from the “intention to treat” analysis. By 
removing these participants from the study’s denominator, the proportion of 
successful procedures appears higher than it really is. In addition, 30% of enrolled
women did not complete 5 year follow-up, and these women may have had more 
problems than women who completed follow-up.
We agree with the authors’ hypothesis that some women may not consider 
laparoscopic sterilization due to the need to have the procedure in the operating 
room, receive general anesthesia or miss work. Yet the authors do not report how
many of the procedures they studied were done in the office versus operating 
room, information about anesthesia used, or days of missed work.
While we appreciate the authors’ reference to our previous publications on the 
topic, we feel that our results were misrepresented, perhaps due to a 
misunderstanding of our methodology [2,3]. Our Markov models incorporated all 
relevant data available in the published literature, including data from the 
manufacturer of Essure. We also performed extensive sensitivity analyses in both 
studies to assess the impact on our findings when varying the value of key 
variables over plausible ranges, rather than relying on single parameter 
assumptions. Moreover, we disagree with the statement that our “models 
accentuate poor HSG follow-up with hysteroscopic sterilization” [1]. Based on 
published data that were available at the time of publication on the proportion of 
women completing HSG follow-up while considering the study size to ensure that 
findings from a small study do not “count” as much as findings from larger 
studies, we estimated that on average 79% (range 13-94%) of women returned 
for the recommended HSG at 3 months [3].  Similarly, our “projected pregnancy 
rates” are based on published data reported in the literature, including 
pregnancies reported by the manufacturer on their website [4]. Indeed, data from
Chudnoff et al. [1] support findings from our studies. For example, Chudnoff et al 
report that 81% (421/518) of women were able to rely on the procedure at 3 
months post-procedure [1]. This finding confirms our first Markov model which 
predicted that approximately 85% of women undergoing attempted hysteroscopic
sterilization would be able to rely on the procedure for contraception at 3 months 
post-procedure [2].    
In addition, the authors incorrectly state that our models do not include 
complication rates. Both major and minor complications related to hysteroscopic 
and laparoscopic sterilization were incorporated in the first Markov model [2], and 
we found no significant difference in complications between the two procedures 
based on the data available at that time [2]. In contrast, inherent in Chudnoff et 
al’s discussion of complications is the assumption that there are fewer 
complications with hysteroscopic than laparoscopic sterilizations. Although 
Chudnoff, et. al., discuss 457 adverse events related to hysteroscopic sterilization 
with Essure reported on the Manufacturer and User Facility Device Experience 
(MAUDE) database, the FDA recently updated this number to 5093 adverse events 
reported since the 2002 approval [5]. This increase in adverse events has 
prompted the FDA to convene a public meeting of its Obstetrics and Gynecology 
Devices Panel on September 24, 2015 to discuss data regarding Essure’s safety 
and effectiveness.  
As 750,000 women have undergone hysteroscopic sterilization worldwide since 
2001, evaluating the safety and effectiveness of hysteroscopic sterilization is of 
great importance. We still lack data about the short and long-term side effects, 
safety, need for further surgery including hysterectomy, and risk of pregnancy in 
women who attempt Essure, not just a subset of those that have successful 
placement and receive follow-up with confirmation of tubal blockage. Women and 
their physicians need this essential information to truly make informed decisions 
regarding choice of sterilization procedure.
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